Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.

Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.

Item
http://www.wikidata.org/entity/Q34552023
Standing genetic variation and the evolution of drug resistance in HIVPharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.Health and treatment implications of food insufficiency among people living with HIV/AIDS, Atlanta, Georgia.A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteersEffect of pregnancy on cytochrome P450 3a and P-glycoprotein expression and activity in the mouse: mechanisms, tissue specificity, and time course.Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavirDifferential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.Human Immunodeficiency Virus Gag and protease: partners in resistance.Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomersNeurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation ProcessDaily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir.Factors influencing HAART adherence among private health care sector patients in a suburb of the Ethekwini Metro.Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice.
P2860

Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.

Item
http://www.wikidata.org/entity/Q34552023
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Combination of protease inhibi ...... etics and clinical experience.
@ast
Combination of protease inhibi ...... etics and clinical experience.
@en
Combination of protease inhibi ...... etics and clinical experience.
@nl
type
label
Combination of protease inhibi ...... etics and clinical experience.
@ast
Combination of protease inhibi ...... etics and clinical experience.
@en
Combination of protease inhibi ...... etics and clinical experience.
@nl
prefLabel
Combination of protease inhibi ...... etics and clinical experience.
@ast
Combination of protease inhibi ...... etics and clinical experience.
@en
Combination of protease inhibi ...... etics and clinical experience.
@nl
P1433
P1476
P2093
P304
P31
P433
P478
P577
P698
P1433
P1476
Combination of protease inhibi ...... etics and clinical experience.
@en
P2093
P304
P31
P433
P478
P577
P698